Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$0.86
$2.21
$37.35
$6.75M0.02206,730 shs31,300 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
$1.16
$0.16
$3.32
$330K1.6611,347 shs107,749 shs
PolarityTE, Inc. stock logo
PTE
PolarityTE
$0.37
$0.20
$1.90
$1.78M1.15249,591 shs8.50 million shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.83
+4.9%
$0.71
$0.36
$737.44
$2.89M0.72.41 million shs13.22 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00%0.00%0.00%0.00%0.00%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-4.38%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00%0.00%0.00%0.00%-88.00%
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00%0.00%0.00%0.00%0.00%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
+8.22%-1.00%+33.45%-33.05%-99.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
3.1081 of 5 stars
3.05.00.00.03.80.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00
N/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00
N/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0042,139.92% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$4.64M0.00N/AN/A$9.75 per share0.00
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/A($8.29) per shareN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$38.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)

Latest PTE, KRBP, WINT, BBI, and GENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
6.36
6.36
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/A
0.16
0.22
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/A
4.11
4.11
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.25
0.25

Institutional Ownership

CompanyInstitutional Ownership
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
10.91%
PolarityTE, Inc. stock logo
PTE
PolarityTE
11.75%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
162.87 million2.74 millionNot Optionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
601.57 million1.22 millionNot Optionable
PolarityTE, Inc. stock logo
PTE
PolarityTE
427.38 million6.98 millionOptionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million3.65 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Brickell Biotech stock logo

Brickell Biotech NASDAQ:BBI

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Kiromic BioPharma stock logo

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

PolarityTE stock logo

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.83 +0.04 (+4.89%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 +0.07 (+8.01%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.